Showing results (961-970 of 5,983) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|May 6, 2010
Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulinPei Pei Gan, Joshua A McCarroll, Sela T Po'uha, et al.
Molecular Cancer Therapeutics|May 6, 2010
17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen speciesTeneille Walker, Clint Mitchell, Margaret A Park, et al.
Molecular Cancer Therapeutics|June 16, 2011
Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycinShripad V Bhagwat, Prafulla C Gokhale, Andrew P Crew, et al.
Molecular Cancer Therapeutics|June 16, 2011
A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancerManuel Hidalgo, Elizabeth Bruckheimer, N V Rajeshkumar, et al.
Molecular Cancer Therapeutics|May 21, 2011
Silencing IL-13Rα2 promotes glioblastoma cell death via endogenous signalingLinda C Hsi, Suman Kundu, Juan Palomo, et al.
Molecular Cancer Therapeutics|June 15, 2011
Neutralizing monoclonal antibody to periostin inhibits ovarian tumor growth and metastasisMin Zhu, Romaine E Saxton, Lillian Ramos, et al.
Molecular Cancer Therapeutics|February 2, 2012
Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic backgroundBarry R Davies, Hannah Greenwood, Phillippa Dudley, et al.
Molecular Cancer Therapeutics|January 13, 2012
(212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal diseaseKwon Joong Yong, Diane E Milenic, Kwamena E Baidoo, et al.
Molecular Cancer Therapeutics|January 13, 2012
Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer modelsJoseph M Gozgit, Matthew J Wong, Lauren Moran, et al.
Molecular Cancer Therapeutics|January 13, 2012
MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cellsChin-Tung Chen, Hyaehwan Kim, David Liska, et al.
Pageof 599